通过放射增敏策略改善胰腺癌放射治疗
本文综述了胰腺癌放射治疗中放射增敏策略的研究进展,涵盖传统化疗药物、DNA损伤反应抑制剂、细胞周期检查点抑制剂、高原子序数纳米颗粒、免疫检查点抑制剂联合免疫治疗以及靶向肿瘤微环境和代谢特征等多种途径,旨在增强放疗对胰腺导管腺癌的杀伤效果并克服放疗抵抗。
要点
- 放射增敏旨在增强放疗诱导的DNA损伤、阻止其修复或削弱肿瘤放疗抵抗相关组分。
- 策略包括传统化疗药、DNA损伤反应和细胞周期检查点抑制剂、高原子序数纳米颗粒。
- 免疫检查点抑制剂联合免疫治疗及靶向肿瘤微环境或代谢特征也是增敏途径。
核心结论
- 放射增敏策略有望改善胰腺癌放射治疗效果,但相关策略多处于从临床前研究向临床试验转化的阶段。
研究设计与样本
- 本文为综述,汇总放射增敏策略从初始临床前研究到当前临床试验状态的进展。
主要发现
- 尽管放疗技术可提高剂量并保护邻近正常器官,胰腺癌局部控制仍是问题,凸显改进当前放疗方式的必要性。
- 放射增敏可通过传统化疗药物或抑制DNA损伤反应效应器及细胞周期检查点的新分子实现。
- 高原子序数纳米颗粒有潜力作为放射增敏剂,特异性地增强肿瘤细胞内的放疗效果。
- 免疫治疗联合免疫检查点抑制剂可增强放疗的免疫调节作用。
- 靶向肿瘤微环境组分或与放疗抵抗相关的代谢特征也可能增强胰腺导管腺癌的放射敏感性。
临床怎么用
- 胰腺癌放疗的应用在很大程度上仍取决于机构和提供者,临床决策需结合具体情况。
- 放射增敏策略为改善胰腺癌放疗效果提供了从化疗、靶向、纳米颗粒到免疫联合的多条潜在途径。
局限性
- 原文未系统报告各放射增敏策略的具体疗效数值或临床终点数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation therapy (RT) is a mainstay of treatment for a myriad of cancers; however, it remains a controversial option in the management of patients with pancreatic cancer. The prognosis for this disease remains one of the poorest, despite recent advances in chemotherapy, which still has limited efficacy and suffers from multiple forms of resistance. The application of RT in patients with pancreatic cancer remains largely institution and provider dependent. Despite advances in RT where higher doses can be delivered while sparing adjacent normal organs, local control remains a problem, highlighting the necessity for improvements in the current RT approach. Emerging strategies are currently being developed with the aim of improving the effects of RT using "radiosensitization" mechanisms. The objective of radiosensitization is to either enhance DNA damage induced by RT or to prevent its repair or to impair the RT-resistance-associated components of the tumor. The process of radiosensitization can be achieved through the use of conventional chemotherapy agents or by novel molecules that inhibit DNA damage response effectors, as well as cell cycle checkpoints. Additionally, nanoparticles with a high atomic number have the potential to act as radiosensitizers by enhancing the effects of RT specifically in tumor cells. Another avenue of radiosensitization entails the combination of immunotherapy with immune checkpoint inhibitors to increase the immunomodulatory impact of RT. The radiosensitivity of pancreatic ductal adenocarcinoma may also be enhanced by targeting components of the tumor microenvironment or metabolic characteristics associated with resistance to RT. This review aims to provide a comprehensive overview of cutting-edge radiosensitization strategies, from their initial preclinical studies to their current status in clinical trials.
引用
- Dardare J, Martz N, Witz A, et al. Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. Int J Radiat Oncol Biol Phys. 2025. PMID: 40967374. doi:10.1016/j.ijrobp.2025.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。